AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16988537
Drug: Xanax XR
RxNorm normalized name: Xanax XR
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xanax XR 1 mg and 3 mg
Trial: 9122904
Drug: G-CSF at
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF at doses of 2, 5, 7.5, or 10 micrograms per kg per day for 5 days
Trial: 9122904
Drug: G-CSF at
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF at doses of 7.5 or 10 micrograms per kg per day for both courses
Trial: 30929067
Drug: Iodine-fortified toddler
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine-fortified toddler milk (21.1 µg iodine/100 g prepared drink)
Trial: 18438853
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (OASIS study, untreated with anti-TNFalpha agents)
Trial: 11045316
Drug: Oral calcitriol
RxNorm normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcitriol (p.o. calcitriol)
Trial: 9363869
Drug: Warfarin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin with chemotherapy and radiation therapy
Trial: 1607916
Drug: Idarubicin (IDR)
DrugBank: Idarubicin (DB01177)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Idarubicin (IDR) 12 mg/m2 daily for the first 3 days, followed by consolidation with IDR 15 mg/m2 on the first day of each cycle.
Trial: 1607916
Drug: Daunorubicin (DNR)
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin (DNR) 45 mg/m2 daily for the first 3 days, followed by consolidation with DNR 50 mg/m2 on the first day of each cycle.
Trial: 1607916
Drug: Late intensification
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late intensification (same drugs as induction, CA for 5 days and anthracycline for 2 days).
Trial: 23270519
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg extended-release guaifenesin, every 12 hours for 7 days
Trial: 20643005
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg rocuronium (group R)
Trial: 12238266
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg atracurium (group A)
Trial: 18319587
Drug: Meal-replacement diet
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meal-replacement diet group (MRD-G; n = 60)
Trial: 18319587
Drug: Low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie diet group (LCD-G; n = 30)
Trial: 19496195
Drug: Percutaneous ablation
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous ablation of feeding artery (PAA) before routine RFA treatment
Trial: 19496195
Drug: Routine RFA
RxNorm normalized name: Rfaudraksha resin
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine RFA treatment
Trial: 21475970
Drug: Bupropion (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion (300 mg/day)
Trial: 9569080
Drug: Neoral (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral (5 mg/kg/day, administered q.12.h)
Trial: 9569080
Drug: Prednisolone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (2 mg/kg/day) plus cyclophosphamide (2 mg/kg/day)
Trial: 8045142
Drug: Amrinone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone 0.5 mg/kg followed by 5 micrograms/kg/min
Trial: 8045142
Drug: Amrinone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone 0.5 mg/kg followed by 10 micrograms/kg/min
Trial: 8045142
Drug: Amrinone 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone 1.0 mg/kg followed by 10 micrograms/kg/min
Trial: 3214958
Drug: Standard short-contact
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard short-contact dithranol therapy
Trial: 31756059
Drug: Standard-dose bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard-dose bevacizumab (10 mg/kg 2-weekly)
Trial: 31756059
Drug: Reduced-dose bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reduced-dose bevacizumab (5 mg/kg 2-weekly)
Trial: 22309046
Drug: Clopidogrel (0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (0.20 mg/kg/day)
Trial: 16205095
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) therapy; mean duration: 8.8 (1.7) years
Trial: 16205095
Drug: Untreated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated group (no GH therapy)
Trial: 8551492
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium (50 mg titrated to 100 mg)
Trial: 8551492
Drug: Felodipine ER
RxNorm normalized name: Felodipine ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine ER (5 mg titrated to 10 mg)
Trial: 396063
Drug: Saralasin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saralasin (both doses)
Trial: 24266074
Drug: Sacral canal
RxNorm normalized name: Canalevia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacral canal injection
Trial: 31486420
Drug: CO2-laser myringotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2-laser myringotomy on the 3rd day of hospital treatment
Trial: 31486420
Drug: CO2-laser myringotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2-laser myringotomy on the 7th day of hospital treatment
Trial: 19480558
Drug: Intranasal dosing
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dosing of PF-219061
Trial: 17461981
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg (SIMVA)
Trial: 17461981
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of simvastatin 40 mg and ezetimibe 10 mg (EZE/SIMVA)
Trial: 17461981
Drug: No lipid-lowering
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid-lowering drugs (NLLD)
Trial: 8010332
Drug: Beta-carotene (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene (300 mg daily for 30 days)
Trial: 8010332
Drug: Wheat germ
RxNorm normalized name: Wheat Germ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat germ oil capsules (control group)
Trial: 30293449
Drug: MSN (extended-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSN (extended-release morphine sulfate with sequestered naltrexone)
Trial: 27847195
Drug: Augmented Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented Cognitive Behavioral Therapy (CBT)
Trial: 19133873
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day elemental zinc syrup for 10 weeks
Trial: 19133873
Drug: Placebo syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo syrup without zinc for 10 weeks
Trial: 11574498
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg gemeprost
Trial: 9822168
Drug: Radiotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy alone (median dose 4470 cGy)
Trial: 7664428
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment (sedation and blood pressure control)
Trial: 10423058
Drug: Medical and
RxNorm normalized name: allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen Medicated Patch [Stratagraft]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical and surgical therapy
Trial: 2751284
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g azlocillin every 6 h
Trial: 2751284
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g azlocillin every 8 h
Trial: 73744
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no A.C.T.H. administration)
Trial: 73744
Drug: Total-hip replacement
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total-hip replacement with A.C.T.H. administration
Trial: 30950165
Drug: Antenatal milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antenatal milk expression (AME) intervention involving demonstration and practice with a lactation consultant, reinforcement at weekly visits until delivery, and daily home practice.
Trial: 22500884
Drug: Degarelix (240/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix (240/80 mg)
Trial: 28394498
Drug: Goserelin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin (3.6 mg) plus Bicalutamide (50 mg)
Trial: 23395281
Drug: Prednisone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (1 mg/kg/d, orally)
Trial: 23395281
Drug: Allopurinol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (100 mg, thrice daily, orally)
Trial: 16739846
Drug: Warming needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming needle moxibustion plus western medicine
Trial: 15119917
Drug: IVIG (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG (1 g/kg on 2 consecutive days)
Trial: 15592696
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam irradiation (EBI) combined with interstitial HDR brachytherapy boost (mean dose 18 Gy)
Trial: 15592696
Drug: Sole brachytherapy
RxNorm normalized name: English sole
DrugBank: English sole (DB10904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sole brachytherapy (mean dose 28 Gy)
Trial: 2661966
Drug: oral cyclical
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral cyclical combination of estradiol valerate and cyproterone acetate
Trial: 2661966
Drug: percutaneous 17
RxNorm normalized name: PERCUTANEOUS INTRODUCER SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: percutaneous 17 beta‐estradiol, supplemented by oral progesterone during the second year
Trial: 3308164
Drug: percutaneous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: percutaneous placebo cream
Trial: 31138727
Drug: Atezolizumab-chemotherapy
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab-chemotherapy
Trial: 31138727
Drug: Atezolizumab-bevacizumab-chemotherapy
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab-bevacizumab-chemotherapy
Trial: 28365464
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU), mainly individual-based cognitive behavioural therapy (CBT)
Trial: 23232827
Drug: Early steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early steroid (mometasone furoate 50 µg/nostril/d starting on postoperative day 1)
Trial: 23232827
Drug: Late steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late steroid (mometasone furoate 50 µg/nostril/d starting on postoperative day 7)
Trial: 23232827
Drug: Early steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early steroid
Trial: 19487710
Drug: No hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormone therapy suspension (n = 567)
Trial: 19487710
Drug: 1 month
RxNorm normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 month hormone therapy suspension (n = 570)
Trial: 19487710
Drug: 2 months
RxNorm normalized name: Elecare HMO 0-12 Months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 months hormone therapy suspension (n = 567)
Trial: 17557039
Drug: Topical mesalazine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical mesalazine alone
Trial: 17557039
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with mesalazine plus symbiotic (zir fos)
Trial: 14765315
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin injection (50 units delivered via two 25-U injections of 0.25 ml each into the pancreatic sphincter)
Trial: 14765315
Drug: Sham saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham saline injection (0.50 ml of saline injected into the duodenal lumen)
Trial: 19801024
Drug: Percutaneous Coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous Coronary Intervention (PCI) plus Optimal Medical Therapy (OMT)
Trial: 15121136
Drug: Overnight switch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overnight switch to oxcarbazepine monotherapy
Trial: 15121136
Drug: Progressive switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive switch to oxcarbazepine monotherapy
Trial: 11859850
Drug: Desogestrel-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desogestrel-containing oral contraceptives
Trial: 11887980
Drug: Progestagen-only preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestagen-only preparations (150 microg desogestrel)
Trial: 2938985
Drug: Levonorgestrel-containing oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel-containing oral contraceptives
Trial: 9783333
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg dexamethasone once a day for 4 days
Trial: 8148710
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution containing glucose
Trial: 8148710
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution containing rice
Trial: 8148710
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration solution containing glycine
Trial: 8148710
Drug: Carbohydrate free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate free solution
Trial: 28833829
Drug: 18 F‐FDG‐PET‐guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 F‐FDG‐PET‐guided dose painting (DPBC or DPBN)
Trial: 28833829
Drug: 18 F‐FDG‐PET-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 F‐FDG‐PET-guided dose painting (DPBC or DPBN)
Trial: 21823283
Drug: Acupoint injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint injection desensitization with autoblood (AJA)
Trial: 21823283
Drug: Medicine group
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine group (Dexamethasone Acetate cream and Setastine Hydrochloride)
Trial: 17958029
Drug: DPP-IV resistant
RxNorm normalized name: L-DPPG-Na
DrugBank: Sodium 1,2-Dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DB14105)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP-IV resistant GLP-1 analogues (e.g., exenatide)
Trial: 17958029
Drug: DPP-IV inhibitors
RxNorm normalized name: Dipeptidyl peptidase 4 (DPP-4) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DPP-IV inhibitors (gliptins)
Trial: 17958029
Drug: Sitagliptin (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (first DPP-IV inhibitor)
Trial: 15266329
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment (5-year duration)
Trial: 15266329
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (hormone-receptor-negative tumours, no further therapy)
Trial: 15266329
Drug: Chemotherapy-induced ovarian
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-induced ovarian dysfunction (amenorrhoea)
Trial: 7931480
Drug: Vinorelbine (VRL)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (VRL) administered by continuous infusion (CIV) at a maximum-tolerated dose (MTD) of 8 mg/m2 bolus plus 10 mg/m2/d for 4 days (total dose per cycle, 48 mg/m2)
Trial: 7931480
Drug: Vinorelbine (VRL)
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vinorelbine (VRL) at different dose levels (DL)
Trial: 3126220
Drug: Chlorpheniramine, 4
RxNorm normalized name: Chlorpheniramine, 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine, 4 mg three times a day
Trial: 22717726
Drug: Magnesium sulphate
RxNorm normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium sulphate 45 mg kg(‐1) in 100 ml of isotonic saline
Trial: 20047523
Drug: Perceived oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perceived oral health
Trial: 20047523
Drug: Perception of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perception of oral health
Trial: 20047523
Drug: Relationship between
RxNorm normalized name: CYCLIZED P12 (PEPTIDE BOND BETWEEN THE CARBOXY AND AMINO-TERMINAL ENDS OF THE LINEAR PEPTIDE PSHISKYILRWRPK)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relationship between gingival bleeding and perceived oral health
Trial: 15994252
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no CPAP treatment)
Trial: 12905750
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g propacetamol in 100 ml normal saline intravenously
Trial: 12905750
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg dolantin intramuscularly
Trial: 12905750
Drug: 1.6 g
RxNorm normalized name: GLYCERIN 1241.6 g in 1 L TOPICAL LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 g mannitose in 100 ml NS intravenously as placebo control to propacetamol
Trial: 8913990
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (moderate dose of alcohol 0.56 g/kg)
Trial: 8913990
Drug: Group AC
RxNorm normalized name: Menveo (Men-ACYW), group ACYW intramuscular solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group AC (moderate dose of alcohol 0.56 g/kg with expectancy challenge)
Trial: 8913990
Drug: Group NT
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group NT (no treatment, no alcohol)
Trial: 1487552
Drug: Pyrazinoylguanidine (PZG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrazinoylguanidine (PZG) 600 mg twice daily for 4 weeks
Trial: 3897960
Drug: Cefoxitin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin (30 mg/kg intravenously over 30 minutes, one hour before surgery, and 30 mg/kg over one hour, 3 hours, and 6 hours after initial infusion)
Trial: 3897960
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no routine intra or postoperative antibiotics)
Trial: 30577943
Drug: Increased frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased frequency of IPT‐A (twice per week)
Trial: 30577943
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of fluoxetine
Trial: 29388275
Drug: 150 min·wk‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 min·wk‐1 of aerobic exercise (low-dose)
Trial: 29388275
Drug: 300 min·wk‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 min·wk‐1 of aerobic exercise (high-dose)
Trial: 25218903
Drug: Ozone preconditioning
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone preconditioning (Major Auto-Hemotherapy, 35µg/ml)
Trial: 10450276
Drug: Tetrabenazine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrabenazine (mean dose = 57.9 mg/day, duration = mean 20.3 weeks)
Trial: 10450276
Drug: Tetrabenazine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrabenazine (mean dose = 57.9 mg/day)
Trial: 17934156
Drug: Negative-pressure wound
RxNorm normalized name: Microcyn Negative-Pressure Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-pressure wound therapy (NPWT) delivered through the V.A.C. Therapy System (n = 77)
Trial: 17934156
Drug: Standard moist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard moist wound therapy (MWT) (n = 85)
Trial: 16503775
Drug: Topical cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cyclosporin 0.05%
Trial: 14517597
Drug: Oral risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral risedronate 5 mg/day for 12 months